Skip to main content
Premium Trial:

Request an Annual Quote

Diagnostic Solutions Laboratory, MD Anderson Coronavirus Tests Get FDA Emergency Use Authorizations

NEW YORK — The US Food and Drug Administration has granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Diagnostic Solutions Laboratory and the University of Texas MD Anderson Cancer Center.

Diagnostic Solutions' DSL COVID-19 assay is designed to detect the SARS-CoV-2 nucleocapsid (N) and spike genes in upper respiratory specimens, such as nasal swabs, and bronchioalveolar lavage. It uses Thermo Fisher Scientific's KingFisher nucleic acid extraction instrument with Omega Bio-Tek's MagBind Viral DNA/RNA 96 Kit extraction reagents and runs on Thermo Fisher's Applied Biosystems QuantStudio 5 Real-Time PCR system.

The MD Anderson High-throughput SARS-CoV-2 RT-PCR Assay detects two targets in the virus' N gene in upper respiratory specimens. It uses Hamilton Robotics' MicroLab Starlet automated liquid handler for RNA extraction and PCR reagent preparation, and runs on either the QuantStudio 7 Fast Flex RT-PCR system, the Applied Biosystems 7500 RT-PCR system, or the QuantStudio Dx RT-PCR system with 96-well fast block.

Both tests may only be performed by their developers, according to the FDA.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.